Biomarkers will be critical to developing precision medicine for Alzheimer’s disease, and phosphorylated tau (P-tau) may enable earlier and more accurate detection, according to Eli Lilly-associated researchers.
Researchers with Pfizer and IBM developed an artificial intelligence (AI) model that they claim can predict the eventual onset of Alzheimer’s disease with 71% accuracy based on a language sample.
Beckman Coulter will be using a grant from BARDA (the Biomedical Advanced Research and Development Authority, a division of the Dept. of Health and Human Services) to validate the ability of the company’s Monocyte Distribution Width (MDW) hematology biomarker to aid in the rapid detection of a rare but serious complication of Covid-19 affecting children.
Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Progentec Diagnostics Inc. launched a novel blood test to determine the likelihood that a patient with systemic lupus erythematosus (commonly known as both SLE and lupus) will experience an immunologic disease flare during the coming 12 weeks.
AstraZeneca and Merck announced positive five-year follow-up data from the Phase III SOLO-1 trial which demonstrated a long-term progression-free survival benefit of Lynparza as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.
According to a study published in Nature Communications, enzymes that are used by bacteria to break down mucus in the gut can potentially be useful biomarkers for intestinal diseases.
The Consistent Testing Terminology Working Group published a white paper with industry-wide recommendations for precision medicine testing terms to be utilized in patient education and communication.
AC Immune initiated the second highest dosing group in the company’s Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease, based on encouraging interim data from the initial dosing cohort.